XOMA Limited ( XOMA)

Q3 2011 Earnings Call

November 9, 2011 4:30 pm ET


Carol DeGuzman – Senior Director, Investor Relations

John Varian – Interim Chief Executive Officer

Fred Kurland – Vice President, Finance and Chief Financial Officer

Paul Rubin – Vice President, Clinical Development and Chief Medical Officer


Christopher James – MLV & Company

Matthew Kaplan – Ladenburg Thalmann & Co.

Richard Lau – Wedbush Morgan Securities

Jason Kantor – RBC Capital Markets



Good day, ladies and gentlemen, and welcome to the XOMA’s Quarterly Conference Call. At this time, all lines are in a listen-only mode. Later, we will conduct question-and-answer session and instructions will be given at those times. (Operator instructions) As a reminder, today’s conference call is being recorded.

I would now like to turn the conference over to your host today Carol DeGuzman, Senior Director, Investor Relations. Please begin.

Carol DeGuzman

Thank you, operator, and good afternoon everyone. A short while ago, we issued two news releases, one regarding our financial results for the third quarter of 2011, and one regarding our expanded plans for the development of gevokizumab, which is the official name for XOMA 052 as designated by the U.S. Adopted Names Council.

Today’s webcast includes a slide presentation, which you are invited to view along with the audio. You can access the slide now at the Investor’s tab of our website www.xoma.com. The audio replay and slides also will be available on the website through approximately February 9, 2012. In addition, our quarterly report, Form 10-Q has been filed with the Securities and Exchange Commission this afternoon, and also will be available on our website.

Joining me on today’s call is John Varian, our Interim Chief Executive Officer; Fred Kurland, our Vice President and Chief Financial Officer; and Dr. Paul Rubin, our Vice President, Clinical Development and Chief Medical Officer.

If you liked this article you might like

XOMA (XOMA) Weak On High Volume

Xoma Stock Soaring on Q4 Earnings Beat

Xoma Stock Surges in After-Hours Trading on Q4 Results

Friday Small-Cap Focus: Xoma

Friday Small-Cap Focus: Xoma

Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million